On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act
Secretary, Department of Health v Medtronic Australasia Pty Ltd [2024] FCA 1096 Date of decision: 19 September 2024 Body: Federal Court of...